Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

RIY Lieverse; EJ Van Limbergen; CJG Oberije; EGC Troost; SR Hadrup; AMA Dingemans; LEL Hendriks; F Eckert; C Hiley; C Dooms; Y Lievens; M de Jong; J Bussink; X Geets; V Valentini; G Elia; D Neri; C Billiet; A Abdollahi; D Du Pasquier; P Boisselier; A Yaromina; D De Ruysscher; LJ Dubois; P Lambin

doi:10.1186/s12885-020-07055-1

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

RIY Lieverse, EJ Van Limbergen, CJG Oberije, EGC Troost, SR Hadrup, AMA Dingemans, LEL Hendriks, F Eckert, C Hiley, C Dooms, Y Lievens, M de Jong, J Bussink, X Geets, V Valentini, G Elia, D Neri, C Billiet, A Abdollahi, D Du PasquierP Boisselier, A Yaromina, D De Ruysscher, LJ Dubois, P Lambin

Pulmonary Medicine

Research output: Contribution to journal › Article › Academic › peer-review

25 Citations (Scopus)

3 Downloads (Pure)

Original language	English
Journal	BMC Cancer
Volume	20
Issue number	1
DOIs	https://doi.org/10.1186/s12885-020-07055-1
Publication status	Published - 2020

Access to Document

10.1186/s12885-020-07055-1

Repub_127990_O-A.pdfFinal published version, 946 KB

http://hdl.handle.net/1765/127990

Cite this

Lieverse, RIY., Van Limbergen, EJ., Oberije, CJG., Troost, EGC., Hadrup, SR., Dingemans, AMA., Hendriks, LEL., Eckert, F., Hiley, C., Dooms, C., Lievens, Y., de Jong, M., Bussink, J., Geets, X., Valentini, V., Elia, G., Neri, D., Billiet, C., Abdollahi, A., ... Lambin, P. (2020). Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. BMC Cancer, 20(1). https://doi.org/10.1186/s12885-020-07055-1

@article{d8cd6657916e410394703e82b3b06b14,

title = "Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial",

author = "RIY Lieverse and {Van Limbergen}, EJ and CJG Oberije and EGC Troost and SR Hadrup and AMA Dingemans and LEL Hendriks and F Eckert and C Hiley and C Dooms and Y Lievens and {de Jong}, M and J Bussink and X Geets and V Valentini and G Elia and D Neri and C Billiet and A Abdollahi and {Du Pasquier}, D and P Boisselier and A Yaromina and {De Ruysscher}, D and LJ Dubois and P Lambin",

year = "2020",

doi = "10.1186/s12885-020-07055-1",

language = "English",

volume = "20",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "BioMed Central Ltd.",

number = "1",

}

Lieverse, RIY, Van Limbergen, EJ, Oberije, CJG, Troost, EGC, Hadrup, SR, Dingemans, AMA, Hendriks, LEL, Eckert, F, Hiley, C, Dooms, C, Lievens, Y, de Jong, M, Bussink, J, Geets, X, Valentini, V, Elia, G, Neri, D, Billiet, C, Abdollahi, A, Du Pasquier, D, Boisselier, P, Yaromina, A, De Ruysscher, D, Dubois, LJ & Lambin, P 2020, 'Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial', BMC Cancer, vol. 20, no. 1. https://doi.org/10.1186/s12885-020-07055-1

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. / Lieverse, RIY; Van Limbergen, EJ; Oberije, CJG et al.

In: BMC Cancer, Vol. 20, No. 1, 2020.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

AU - Lieverse, RIY

AU - Van Limbergen, EJ

AU - Oberije, CJG

AU - Troost, EGC

AU - Hadrup, SR

AU - Dingemans, AMA

AU - Hendriks, LEL

AU - Eckert, F

AU - Hiley, C

AU - Dooms, C

AU - Lievens, Y

AU - de Jong, M

AU - Bussink, J

AU - Geets, X

AU - Valentini, V

AU - Elia, G

AU - Neri, D

AU - Billiet, C

AU - Abdollahi, A

AU - Du Pasquier, D

AU - Boisselier, P

AU - Yaromina, A

AU - De Ruysscher, D

AU - Dubois, LJ

AU - Lambin, P

PY - 2020

Y1 - 2020

U2 - 10.1186/s12885-020-07055-1

DO - 10.1186/s12885-020-07055-1

M3 - Article

SN - 1471-2407

VL - 20

JO - BMC Cancer

JF - BMC Cancer

IS - 1

ER -